Expanded access trial in development for radium-223 chloride (Alpharadin) in mCRPC

We have heard from one of our contacts that Bayer Healthcare (presumably in combination with their business partner, Algeta) is initiating an expanded access (compassionate use) trial of injectable radiation therapy with radium-223 chloride (Alpharadin®) for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Full data report from the ALSYMPCA trial of radium-223 presented

According to a company media release, the full results of the ALSYMPCA  trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

FDA fast tracks NDA for Alpharadin in mCRPC

According to a media release issued by Bayer HealthCare, the U. S. Food & Drug Administration (FDA) has given the green light to “fast track” review of the company’s new drug application (NDA) for Alpharadin™ (radium-223 chloride) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Alpharadin shows 2.8-month survival benefit in mCRPC

The investigational radioisotope radium-233 chloride (Alpharadin) has shown a small but clinically significant overall survival benefit in the treatment of men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Algeta completes enrollment in Phase III trial of radium-223 chloride

According to a media release issued by Algeta this week, the company has completed patient enrollment into a large, Phase III trial evaluating radium-223 chloride in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) in which metastases are clearly evident in bone. … READ MORE …

Other Wednesday prostate cancer news: February 4, 2009

In addition to the reports on the early stages of the RALP learning curve and quality of life outcomes post-brachtherapy, there are a large number of additional reports in today’s news: … READ MORE …